Genome & Co.

Founded 2015

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 1
Average round size
info
The average size of a deal this fund participated in
$26M
Portfolio companies 1
Rounds per year 0.17
Lead investments 1
Key employees Soon

Areas of investment

  • Life Science
  • Diabetes
  • Therapeutics
  • Biotechnology
  • Health Care

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Genome & Co.:
Typical Co-investors
Genome & Co. is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Genome & Co.:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Smac Partners Germany, Unterhaching
Temasek Holdings Singapore, Singapore
Secure Octane United States, San Francisco
Cargill Ventures United States, Minnetonka
Culture Convenience Club (CCC) Japan, Tokyo
Tektronix United States, Beaverton
Integrated Retirement Initiatives United States, Baxter
S8 Capital Russia, Moscow
Lilly Ventures United States, Indianapolis
New Orleans Startup Fund United States, New Orleans
Shihaisong Capital -
Jincheng Dingsheng China, Guangdong
Suzhou Nuojin Touzi Youxian Gongsi China, Jiangsu
Mount Kellett Capital Management United States, New York
WISeKey Switzerland, Geneve
Nantong Qixiong China, Nantong
Rowad -
EOS Syndicate Management -
H20 Capital - Investments, Portfolio & Company Exits -
Sick Holding GmbH -

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Scioto Biosciences

Biotechnology
Diabetes
Health Care
Life Science
Therapeutics
1
$26M10 Aug 2020 United States, Indianapolis

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Genome & Co.?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: